Antiphospholipid syndrome in pregnancy: Onset to outcome

Fetal and Maternal Medicine Review

Volumn 15, Issue 3, 2004, Pages 273-297

  Stone, Sophia ^a   Poston, Lucilla ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CARDIOLIPIN ANTIBODY; DALTEPARIN; ENOXAPARIN; HEPARIN; HYDRALAZINE; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PROCAINAMIDE; QUINIDINE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BRAIN HEMORRHAGE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; FETAL HEMORRHAGE; FETUS DEATH; HUMAN; INTRAUTERINE GROWTH RETARDATION; LIVEDO RETICULARIS; NEUROLOGIC DISEASE; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY DISORDER; PREMATURE FETUS MEMBRANE RUPTURE; PRENATAL CARE; PRENATAL DIAGNOSIS; RECURRENT ABORTION; REVIEW; RISK FACTOR; SPONTANEOUS ABORTION; SYMPTOM; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

EID: 8744239575     PISSN: 09655395     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0965539504001317     Document Type: Review

References (107)

1. Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J 1983; 287: 1088-1089.
2. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-44.
3. Hughes GRV. Connective tissue disease and the skin. The 1983 Prosser-White oration. Clin Exp Dermatol 1984; 9: 535-44.
4. Harris EN, Gharavi AE, Hughes GR. Anti-phospholipid antibodies. Clin Rheum Dis 1985; 11: 591-609.
5. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-311.
6. Wasserman A. Uber die entwicklung und den gegenwartigen Stand der Serodiagnostik gegenuber syphilis. Berl Klin Wochenschr 1907; 44: 1599.
7. Pangborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 1941; 48: 484-86.
8. Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis. JAMA 1952; 150: 467-73.
9. Harvey AM, Shulman LE. Connective tissue disease and the chronic biologic false-positive test for syphilis (BFP reaction). Med Clin North Am 1966; 50: 1271-279.
10. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostasis Thromb 1972; 1: 75-95.
11. Conley CL, Hartmann RC. Haemorrhagic disorder caused by a circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-22.
12. Gardiner C, Mackie IJ, Malia RG, Jones DW, Winter M, Leeming D et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000; 111: 1230-235.
13. Beaumont JL. Syndrome haemorrhagique acquis du a un anticoagulant circulant. Sang 1954; 25: 1-15.
14. Bowie EJW, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-30.
15. Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis 1974; 3: 65-93.
16. Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med Scand 1975; 197: 153-59.
17. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1987; 2: 1211-214.
18. Roubey RAS. Hughes Syndrome Antiphospholipid Syndrome. Khamashta MA (ed) London, Springer-Verlag 2000; 1: 253-60.
19. Galli M, Barbui T. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-157.
20. Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood 1994; 84: 2854-867.
21. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-353.
22. Piette JC. Towards improved criteria for the antiphospholipid syndrome. Lupus 1998; 7: S149-S157.
23. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-311.
24. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-43.
25. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001; 27: 499-505.
26. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-279.
27. Khamashta MA. Management of the antiphospholipid syndrome. CPD Bulletin Rheum Arthritis 1999; 1: 22-46.
28. Williams FMK, Hunt BJ. The antiphospholipid syndrome and vascular surgery. Cardiovasc Surg 1998; 6: 10-16.
29. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-308.
30. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-97.
31. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-38.
32. Ruiz-irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164-169.
33. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-715.
34. Kuruvilla A. Warfarin in antiphospholipid antibody syndrome. Lancet 2001; 358: 1461-462.
35. Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood 1993; 81: 2958-963.
36. Greaves M. Antiphospholipid syndrome and thrombosis. Thrombosis 1999; 353: 1348-353.
37. Growther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-138.
38. Moll S and Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulant. Ann Intern Med 1997; 127: 177-85.
39. Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36: 970-982.
40. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A et al. Comparison of the primary and secondary antiphospholipid syndrome: A European Multicenter study of 114 patients. Am J Med 1994; 96: 3-8.
41. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997; 27: 27-35.
42. Vaarala O. antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7: 132-34.
43. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-25.
44. Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. aPL and recurrent abortion. Obstet Gynecol 1991; 77: 854-58.
45. Parke AL, Wilson D, Maier D. The prevalence of aPL in women with recurrent spontaneous abortion, women with succesful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991; 34: 1231-235.
46. Maclean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1997; 89: 549-55.
47. Rai RS, Regan L, Clifford K, Pickering W, Dave M, Mackie I et al. Antiphospholipid antibodies and beta 2-glycoprotein-1 in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod 1995; 10: 2001-2005.
48. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995; 10: 3301-304.
49. Yetman DL Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril 1996; 66: 540-46.
50. Carreras LO, Vermylen J. "Lupus" anticoagulant and prostacyclin. Lancet 1981; 1: 665.
51. Carreras LO, Vermylen J, Spitz B, Van Assche A. "Lupus" anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death. Br J Obstet Gynaecol 1981; 88: 890-94.
52. Lubbe WF, Palmer SJ, Butler WS, Liggins GC. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1983; 1: 1361-363.
53. Branch DW, Scott JR, Kochenour NK, Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med 1985; 313: 1322-326.
54. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-323.
55. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489-93.
56. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982; 142: 829-34.
57. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369-73.
58. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992; 80: 614-20.
59. Lima F, Khamashta MA, Buchanan N, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996; 14: 131-36.
60. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG's (LA) are not directed to phospholipid only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
61. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65: 320-22.
62. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-190.
63. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
64. Harris EN. Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94: 476-84.
65. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-24.
66. Pierangeli SS, Stewart M, Silva LK, Harris EN. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998; 25: 156-60.
67. Kwak JY, Barini R, Gilman-Sachs A, Beaman KD, Beer AE. Down-regulation of maternal antiphospholipid antibodies during early pregnancy and pregnancy outcome. Am J Obstet Gynecol 1994; 171: 239-46.
68. Topping J, Quenby S, Farquharson R, Malia R, Greaves M. Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome. Hum Reprod 1999; 14: 224-28.
69. Out HJ, Bruinse HW, Christiaens GCML, van Vliet M, de Groot PG, Nieuwenhuis HK et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26-32.
70. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 2003; 101: 1333-344.
71. Derksen RHWM, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004; 50: 1028-39.
72. Ordi J, Barquinero J, Vilardell M, Jordana R, Tolosa C, Selva A et al. Fetal loss treatment in patients with antiphospholipid antibodies. Ann Rheum Dis 1989; 48: 798-802.
73. Silveira LH, Hubble CL, Jara LJ, Saway S, Martinez-Osuna P, Seleznick MJ et al. Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Am J Med 1992; 93: 403-411.
74. Hasegawa I, Takakuwa K, Goto S, Yamada K, Sekizuka N, Kanazawa K et al. Effectiveness of prednisolone/aspirin therapy for recurrent aborters with antiphospholipid antibody. Hum Reprod 1992; 7: 203-207.
75. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439-43.
76. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 1993; 169: 1411-417.
77. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JWK, Farewell V. Predisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Eng J Med 1997; 337: 148-53.
78. Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 2002; 99: 135-144.
79. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-589.
80. Rai RS, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-56.
81. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6: 509-13.
82. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gyneacol 1999; 106: 102-107.
83. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. Am J Reprod Immunol 1996; 35: 402-407.
84. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-13.
85. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 2000; 183: 1008-1012.
86. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168: 1265-270.
87. Backos M, Rai R, Thomas E, Murphy M, Dore C, Regan L. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14: 2876-880.
88. Sanson B, Lensing AWA, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al. Safety of low-molecular-weight heparin in pregnancy: A systematic review. Thromb Haemost 1999; 81: 668-672.
89. Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol 2000; 107: 1116-121.
90. Sephton V, Farquharson RG, Topping J, Quenby S, Cowan C, Back DJ, Toh CH. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101: 1307-311.
91. Hunt BJ, Doughty H, Majurndar G, Copplestone A, Kerslake S, Buchanan N et al. Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies. Thromb Haemost 1997; 77: 39-43.
92. Greaves M. Heparin-induced thrombocytopenia and thrombosis. Prescribers' Journal 2000; 40: 59-64.
93. Hung L, Rahimtoola SH. Prosthetic heart valves and pregnancy. Circulation 2003; 107: 1240-246.
94. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33: 1637-641.
95. Brooks C, Rutherford JM, Gould J, Ramsay MM, James DK. Warfarin dosage in postpartum women: a case-control study. Br J Obstet Gynacol 2002; 109: 187-90.
96. Hunt BJ, Khamashta MA, Lakasing L, Williams FMK, Nelson Piercy C, Bewley S et al. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: is warfarin preferable? Thromb Haemost 1998; 79: 1060-1061.
97. Pauzner R, Dulitzki M, Langevitz P, Livneh A, Kenett R, Many A. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001; 86: 1379-384.
98. Clark AL, Branch DW, Silver RM, Harris EN, Pierangeli SS, Spinnato JA. Pregnancy complicated by the antiphospholipid syndrome: Outcome with intravenous immunoglobulin therapy. Obstet Gynecol 1999; 93: 437-441.
99. Gordon C, Raine-Fenning N, Brackley K, Bacon PA, Weaver J, Kilby M. Intravenous immunoglobulin (IVIG) therapy to salvage severely compromised pregnancies in SLE and antiphospholipid (APL) syndrome. Lupus 1998; suppl 1: 114.
100. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000; 182: 122-27.
101. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48: 728-31.
102. Harrington K, Cooper D, Lees C, Hecher K, Campbell S. Doppler ultrasound of the uterine arteries: the importance of bilateral notching in the prediction of pre-eclampsia, placental abruption or delivery of a small-for-gestational-age baby. Ultrasound Obstet Gynecol 1996; 7: 182-88.
103. Bower SJ, Bewley S, Campbell S. Improved prediction of preeclampsia by two stage screening of uterine arteries using early diastolic notch and color Doppler imaging. Obstet Gynecol 1993; 82: 78-83.
104. Stone S, Hunt BJ, Khamashta MA, Bewley S, Nelson-Piercy C. Outcome of 35 treated pregnancies in women with primary antiphospholipid syndrome. J Obstet Gynecol 2002; 22: S49.
105. Lindqvist P, Dahlback B, Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999; 94: 595-99.
106. Silver RK, MacGregor SN, Sholls JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obst Gynecol 1993; 169: 1411-417.
107. Edelman P, Rouquette AM. Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management. Clin Rev Obstet Gynecol 1995; 13: 91-99.